Evidence map›Paper›PMID 23418522›Full record

ArticlePloS one2013

Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies.

Štefan Holiga, Karsten Mueller, Harald E Möller, Tomáš Sieger, Matthias L Schroeter, Josef Vymazal, Evžen Růžička, Robert Jech

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Modulation of premotor cortex response to sequence motor learning during escitalopram intake.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Trial
  3. Article
  4. Neuroimaging of Parkinson's disease: Expanding views.Neuroscience and biobehavioral reviews · 2015
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Štefan HoligaMax Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Karsten Mueller
Harald E Möller
Tomáš Sieger
Matthias L Schroeter
Josef Vymazal
Evžen Růžička
Robert Jech
Max Planck Institute for Human Cognitive and Brain Sciences · DECharles University · CZNa Homolce Hospital · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To tackle the heterogeneity of Parkinson's disease symptoms, most functional imaging studies tend to select a uniform group of subjects. We hypothesize that more profound considerations are needed to account for intra/inter-subject clinical variability and possibly for differing pathophysiological processes. Twelve patients were investigated using functional magnetic resonance imaging during visually-guided finger tapping. To account for disease heterogeneity, the motor score and individual symptom scores from the Unified Parkinson's Disease Rating Scale (UPDRS-III) were utilized in the group-level model using two approaches either as the explanatory variable or as the effect of interest. Employment of the UPDRS-III score and symptom scores was systematically tested on the resulting group response to the levodopa challenge, which further accentuated the diversity of the diseased state of participants. Statistics revealed a bilateral group response to levodopa in the basal ganglia. Interestingly, systematic incorporation of individual motor aspects of the disease in the modelling amended the resulting activity patterns conspicuously, evidencing a manifold amount of explained variability by the particular score. In conclusion, the severity of clinical symptoms expressed in the UPDRS-III scores should be considered in the analysis to attain unbiased statistics, draw reliable conclusions and allow for comparisons between research groups studying Parkinson's disease using functional magnetic resonance imaging.

Indexed as

Antiparkinson AgentsBasal GangliaCarbidopaDisability EvaluationHumansLevodopaMagnetic Resonance ImagingMaleMiddle AgedParkinson DiseasePsychomotor PerformanceReproducibility of ResultsSensitivity and SpecificitySeverity of Illness IndexAntiparkinson AgentsCarbidopaLevodopa

Identifiers

PMID23418522
PMCPMC3572025
OpenAlexW2063142263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.